Boston Scientific has begun a deal to acquire Intera Oncology, a privately held company that offers the Intera 3000 hepatic artery infusion pump and floxuridine, both of which are U.S. Food and Drug Administration (FDA) approved.

Specific details of the transaction was not disclosed.

The Intera 3000 pump administers hepatic artery infusion (HAI) therapy to treat liver tumors primarily caused by metastatic colorectal cancer. The pump is implanted under the skin and a connected catheter is then placed in the hepatic artery, which supplies the liver with oxygenated blood. The pump provides a continuous flow of floxuridine directly into the liver to treat tumors that have metastasized, typically from the colon.

According to Intera, its pump is the only constant flow implantable pump for HAI therapy approved in the U.S. Its safety and effectiveness is backed by trial data showing HAI therapy’s clinical benefits for patients with unresectable colorectal metastases to the liver, both prior to and following resection.

Data from the trials highlighted that HAI therapy “significantly improves” tumor response, time to progression, and overall survival compared to systemic chemo, the company said. Current Phase II and III studies are assessing HAI therapy in larger patient groups for first-line, second-line, and post-surgery adjuvant treatments.

Boston Scientific said it plans to finish the transaction in H1 2025. It’s expected to be immaterial to adjusted earnings per share (EPS) in 2025 and more dilutive on a GAAP basis because of acquisition-related net charges and amortization expense.

“Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients,” said Peter Pattison, president, Interventional Oncology and Embolization, Boston Scientific. “Interest in HAI therapy has grown in the oncology community given improved techniques, positive clinical results and ongoing trials. We believe this acquisition will enable us to provide a more comprehensive set of solutions to physicians and their patients to treat both primary and metastatic forms of liver cancer.”